



administration of a 0.5 g dose. No accumulation of meropenem in plasma or urine was observed with regimens using 0.5 g administered every 8 hours or 1 g administered every 6 hours in volunteers with normal renal function.

The only metabolite of meropenem is microbiologically inactive.

Meropenem penetrates well into most body fluids and tissues including cerebrospinal fluid of patients with bacterial meningitis, achieving concentrations in excess of those required to inhibit most bacteria.

Studies in children have shown that the pharmacokinetics of meropenem in children are similar to those in adults. The elimination half-life for meropenem was approximately 1.5 to 2.3 hours in children under the age of 2 years and the pharmacokinetics are linear over the dose range of 10 to 40 mg/kg.

Pharmacokinetic studies in patients with renal insufficiency have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with renal impairment.

Pharmacokinetic studies in the elderly have shown a reduction in plasma clearance of meropenem, which correlated with age-associated reduction in creatinine clearance.

Pharmacokinetic studies in patients with liver disease have shown no effects of liver disease on the pharmacokinetics of meropenem.

### Expiry date and storage conditions

See the expiry date printed on the outer carton.

This date refers to the product correctly stored in unopened package.

Beware not to use **Aropem** after this date.

Store below 30°C. Do not freeze.

Keep all medicines out of reach of children.

It is recommended to use freshly prepared solutions of **Aropem** for I.V. injection or infusion. Reconstituted product may be stored for up to 2 hours at controlled room temperature (15-25°C) or for up to 12 hours if kept in a refrigerator (4°C).

Diluents	Stability (hours)	
	At temperatures between 15-25°C	At 4°C
<b>Solutions (1 to 20 mg/ml) prepared with:</b>		
0.9% sodium chloride	4	24
5% glucose	1	4
5% glucose and 0.225% sodium chloride	1	4
5% glucose and 0.9% sodium chloride	1	2
5% glucose and 0.15% potassium chloride	1	6
2.5% or 10% mannitol intravenous infusion	2	16
10% glucose	1	2
5% glucose and 0.02% sodium bicarbonate intravenous infusion	1	6

### Presentation

**Aropem** sterile powder for solution for I.V. injection or infusion is available in packs of 1 vial containing 0.5 g/1 g of meropenem with sodium carbonate.

**Manufactured by: Zambon Switzerland Ltd**

**Cadempino, Switzerland**

**For: ARWAN Pharmaceutical Industries Lebanon s.a.l.**

**Jadra, Lebanon**

### THIS IS A MEDICAMENT

- Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medication.
- The doctor and the pharmacist are experts in medicines, their benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.
- Keep all medicaments out of the reach of children.

**Council of Arab Health Ministers, Union of Arab Pharmacists**